ID
28126
Beschrijving
Study ID: 101468/125 Clinical Study ID: SKF-101468/125 Study Title: A double-blind, multicentre, flexible dose, L-dopa controlled study of ropinirole to investigate A) neuroprotective effect as measured by 3D PET scanning, and B) ophthalmological safety, in patients with early Parkinson’s disease Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: requip
Trefwoorden
Versies (1)
- 20-12-17 20-12-17 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
20 december 2017
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
L-dopa controlled study of ropinirole, neuroprotective effect and ophthalmological safety in early Parkinson’s disease 101468/125
Module 3 Visit 6 Month 6
- StudyEvent: ODM
Beschrijving
Vital signs
Beschrijving
Sitting blood pressure (systolic)
Datatype
integer
Maateenheden
- mmHg
Beschrijving
Sitting blood pressure (diastolic)
Datatype
integer
Maateenheden
- mmHg
Beschrijving
Sitting Heart Rate
Datatype
integer
Maateenheden
- beats/min
Beschrijving
Concomitant Medication
Beschrijving
Adverse Experiences
Beschrijving
Have there been any adverse experiences observed or elicited by the following direct question to the patient: "Have you felt different in any way since your last visit?" Transcribe any ongoing adverse experiences from the previous module, record any changes to ongoing adverse experiences, and details of any new adverse experiences observed or reported by the patient in the Adverse Experiences section towards the back of this module.
Datatype
text
Beschrijving
L-Dopa Rescue
Beschrijving
Patients must complete as a minimum the initial titration to dose level 5. Titration of the dose of study medication to the maximum tolerated dose is encouraged. However if the patients symptoms remain inadequately controlled, open label L-dopa may be prescribed as rescue medication. Transcribe any ongoing L-dopa medication from the previous module, record any changes in L-dopa since the last visit, and details of any L-dopa that the patient has started, or is about to start taking, in the L-dopa Rescue section towards the back of this module.
Datatype
text
Beschrijving
Study Medication Compliance
Beschrijving
End of visit instructions for patients continuing
Beschrijving
NB. this visit must take place at least 6 months after the initial ERG examination. • Tear-out the patient's appointment card (next page) and record the date and time of the appointment and your centre number on the card. If the date and time of the patient's second ERG examination is not yet known, please remember to inform the patient of this information when it becomes available. • lnstruct the patient that they must take their appointment card to their ERG examination visit. • Depending on the dose level that the patient is to take from today, order the second 6 month supply of medication for the patient. • Arrange for the patient to return for their next clinic visit in six months time. • Complete the Patient Continuation/Withdrawal section at the back of this module.
Datatype
date
Beschrijving
End of visit instructions for patients not continuing
Beschrijving
ERG Examintion Appointment Card
Beschrijving
Patient Number
Datatype
integer
Beschrijving
Patient Initials
Datatype
text
Beschrijving
Centre Number
Datatype
integer
Beschrijving
ERG Examination Visit Date and Time
Datatype
datetime
Beschrijving
Doctor´s Contact Number
Datatype
text
Beschrijving
Concomitant Medication
Beschrijving
Transcribe any ongoing concomitant medication from the previous module, and record any concomitant medication changes since the last visit. Any new medical illness/diagnosis or symptoms in the absence of a diagnosis should be recorded in the Adverse Experience section utilising the same terminology. If a medication was marked "Continuing" at the last visit, but has since had a dosage change or has been stopped, it must be recorded as a change with the start and end date. If no concomitant medication answer question appropriately.
Datatype
boolean
Beschrijving
Details on concomitant medication
Beschrijving
Drug Name
Datatype
text
Beschrijving
Total daily dose
Datatype
float
Maateenheden
- mg
Beschrijving
Medical condition
Datatype
text
Beschrijving
Approximate Start Date
Datatype
date
Beschrijving
End Date
Datatype
date
Beschrijving
For SB
Datatype
text
Beschrijving
Levodopa Rescue Therapy
Beschrijving
Details on Levodopa - rescue therapy
Beschrijving
Adverse Experiences
Beschrijving
Details on Adverse Experiences
Beschrijving
Experience
Datatype
text
Beschrijving
For SB
Datatype
text
Beschrijving
Date Started
Datatype
date
Beschrijving
Date Stopped
Datatype
date
Beschrijving
Duration if less than 24hrs
Datatype
float
Maateenheden
- hrs
Beschrijving
Experience continuing?
Datatype
boolean
Beschrijving
Course Continuation
Datatype
boolean
Beschrijving
If not continuing no. of episodes
Datatype
integer
Beschrijving
Intensity
Datatype
integer
Beschrijving
Aktion taken on Study Medication
Datatype
text
Beschrijving
Suspected Relationship
Datatype
integer
Beschrijving
Corrective Therapy
Datatype
text
Beschrijving
Serious Adverse Experience
Datatype
boolean
Beschrijving
AEGIS
Datatype
text
Beschrijving
Investigator´s Signature
Beschrijving
Patient Continuation / Withdrawal
Beschrijving
Is the patient continuing in the study?
Datatype
integer
Beschrijving
Specification of reason for withdrawal
Datatype
integer
Beschrijving
Specification of other reason for withdrawal
Datatype
text
Beschrijving
Date of last dose
Datatype
date
Beschrijving
Investigator´s Signature
Similar models
Module 3 Visit 6 Month 6
- StudyEvent: ODM